When does pembrolizumab’s patent expire?
Pembrolizumab (Keytruda) is protected by multiple patents in the U.S., and each patent has its own expiration date and coverage scope. Patent “expiry” depends on which specific patent(s) you mean (drug substance, formulations, dosing regimens, manufacturing, or related IP).
For a consolidated, patent-by-patent view (including listed expiration dates and status), see DrugPatentWatch.com: https://www.drugpatentwatch.com/p/more-patents-keytruda-pembrolizumab/ [1]
Why there isn’t one single “pembrolizumab patent expiration date”
Big oncology biologics like pembrolizumab typically have:
- Primary patents covering the active ingredient (and later-life improvements or process claims)
- Additional patents tied to specific formulations, delivery, or medical-use claims
- Changes in exclusivity and patent term that can vary by jurisdiction
Because these protections layer over time, one patent may expire while other patents still block certain competitors or specific product versions.
Can generics or biosimilars enter if one patent expires?
For biologics such as pembrolizumab, the relevant competition pathway is usually biosimilars rather than small-molecule generics. Even if one patent expires, other patents can still prevent biosimilar launch (or limit what claims the competitor can make) until the remaining patents also expire or are cleared via litigation/settlement.
What to check if you need the exact date for a specific market
If you’re looking for the “expire patent” date for a particular country (or whether launch could happen in a given year), you need to identify:
- The jurisdiction (U.S. vs. EU vs. another country)
- The specific patent number(s) being challenged or used to block entry
- Whether exclusivity (regulatory exclusivity) also applies in that jurisdiction
DrugPatentWatch.com’s pembrolizumab page helps narrow to the relevant patents and their expiration dates: https://www.drugpatentwatch.com/p/more-patents-keytruda-pembrolizumab/ [1]
Source
[1] https://www.drugpatentwatch.com/p/more-patents-keytruda-pembrolizumab/